Company news
Cosciens Biopharma Inc. (TSX:CSCI) news
Cosciens Biopharma Inc. news releases on 6ix. Latest, Sep 16, 2026: COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
Press releases & updates
COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
September 16, 2026
Canadian Investment Regulatory Organization Trade Resumption - CSCI
September 11, 2026
COSCIENS ACQUIRES NUALTIS CORP.
September 10, 2026
COSCIENS Biopharma Inc. Reports Q2 2026 Results
August 11, 2026
COSCIENS Biopharma Inc. Completes Share Capital Amendment
July 3, 2026
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
June 21, 2026
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
June 18, 2026
COSCIENS Biopharma Inc. Reports Q1 2026 Results
May 12, 2026
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
April 20, 2026
COSCIENS Comments on Unusual Market Activity
April 7, 2026
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 25, 2026
COSCIENS Provides Strategic Update
March 5, 2026
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
December 1, 2025
COSCIENS Biopharma Inc. Announces Leadership Change
November 14, 2025
COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update
November 11, 2025
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
August 14, 2025
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
June 30, 2025
COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders
May 30, 2025
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
May 26, 2025
Goodwood to Nominate New Directors for COSCIENS Biopharma Inc.
May 23, 2025
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
May 13, 2025
COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer
April 14, 2025
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
April 9, 2025
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order
April 1, 2025
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
March 19, 2025
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
March 13, 2025
Canadian Investment Regulatory Organization Trade Resumption - AEZS
December 14, 2023
Canadian Investment Regulatory Organization Trading Halt - AEZS
December 14, 2023
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
January 11, 2023
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
January 12, 2022
IIROC Trade Resumption - AEZS
March 13, 2019
IIROC Trading Halt - AEZS
March 12, 2019
IIROC Trade Resumption - Aeterna Zentaris Inc.
December 21, 2017
IIROC Trade Resumption - AEZS; BNE
December 21, 2017
IIROC Trade Halt - Aeterna Zentaris Inc.
December 20, 2017
CORRECTION FROM SOURCE: IIROC Trade Resumption - Aeterna Zentaris Inc.
May 1, 2017
Research Reports Initiated on Healthcare Stocks Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris
February 24, 2017
IIROC Trade Resumption - AEZ
October 27, 2016
IIROC Trading Halt - AEZ
October 27, 2016
Aeterna Zentaris Affirms Fundamental Strength of Business
November 25, 2015
Aeterna Zentaris Confirms No Corporate Developments
November 24, 2015
Aeterna Zentaris Announces Exercise of Last Series B Warrants Covered by November 1, 2015 Agreement
November 24, 2015
Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen(TM) for the evaluation of AGHD
November 19, 2015
Aeterna Zentaris Announces Details and Implementation of Share Consolidation to Regain NASDAQ Compliance
November 18, 2015
Aeterna Zentaris Announces Shareholder Approval of Share Consolidation
November 16, 2015
Aeterna Zentaris Announces Exercise of Series B Warrants
November 12, 2015
Aeterna Zentaris Urges Shareholders to Vote in Favor of the Share Consolidation and Highlights Support from ISS and Glass Lewis
November 11, 2015
Aeterna Zentaris Reports Third Quarter Financial and Operating Results
November 5, 2015
Aeterna Zentaris Announces Agreement to Exercise Substantially All Remaining Series B Warrants
November 2, 2015
Leading Independent Advisory Firms ISS and Glass Lewis Recommend Shareholders of Aeterna Zentaris Vote FOR Share Consolidation
October 27, 2015